Product Details
Cefepime soidum + tazobactum injection
500MG+62.5MG / 1GM+125MG
Product Description :
CEFEPIME SODIUM + TAZOBACTAM INJECTION
500 mg + 62.5 mg / 1 g + 125 mg
Sterile Powder for Solution for Intravenous or Intramuscular Administration
COMPOSITION
Each vial contains:
Cefepime Sodium equivalent to Cefepime ............... 500 mg
Tazobactam Sodium equivalent to Tazobactam ............... 62.5 mg
or
Cefepime Sodium equivalent to Cefepime ............... 1 g
Tazobactam Sodium equivalent to Tazobactam ............... 125 mg
Excipients: As applicable.
PHARMACEUTICAL FORM
Sterile, white to off-white powder for solution for intravenous or intramuscular administration.
THERAPEUTIC CLASS
Fourth-Generation Cephalosporin Antibiotic + β-Lactamase Inhibitor
INDICATIONS
Cefepime + Tazobactam Injection is indicated for the treatment of moderate to severe bacterial infections caused by susceptible microorganisms.
It may be used in the treatment of:
• Lower respiratory tract infections
• Complicated urinary tract infections
• Intra-abdominal infections
• Skin and soft-tissue infections
• Bone and joint infections
• Septicemia and bloodstream infections
• Febrile neutropenia with suspected bacterial infection
• Serious infections caused by susceptible Pseudomonas aeruginosa
• Other severe bacterial infections caused by susceptible microorganisms
Treatment should be guided by the susceptibility of the causative organism and applicable antimicrobial guidelines.
CONTRAINDICATIONS
Cefepime + Tazobactam is contraindicated in patients with known hypersensitivity to cefepime, tazobactam, other cephalosporins, penicillins, or any component of the formulation.
DRUG INTERACTIONS
Particular consideration may be required with concomitant use of:
• Aminoglycoside antibiotics
• Other nephrotoxic medicines
• Potent diuretics
• Other β-lactam antibiotics
• Anticoagulants such as warfarin
The treating physician should review all concomitant medications before administration.
ADMINISTRATION
Cefepime + Tazobactam Injection may be administered by intravenous or intramuscular route according to the approved product information.
The contents of the vial should be reconstituted with a suitable compatible diluent under appropriate aseptic conditions.
For intravenous administration, the reconstituted solution should be further diluted as required and administered by a qualified healthcare professional according to the approved product information and institutional protocol.
For Intravenous or Intramuscular Use Only.
STORAGE
Store according to the storage conditions stated on the approved product label.
Protect from excessive heat, moisture and light.
After reconstitution/dilution, use within the period specified in the approved product information.
Do not use if the reconstituted solution shows visible particles, precipitation or unexpected discoloration.